Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Artios Pharma | 2025 | Series D | $115.0M | Cambridge |
| Invivyd | 2025 | Post Ipo Equity | $125.0M | Waltham |
| Imbria Pharmaceuticals | 2025 | Series B | Undisclosed | Boston |
| Bambusa Therapeutics | 2025 | Series A | Undisclosed | Boston |
| Biohaven Pharmaceutical | 2025 | Post Ipo Equity | $200.0M | New Haven |
| Azalea Therapeutics | 2025 | Series A | $65.0M | Berkeley |
| Seres Therapeutics | 2025 | Grant | $3.6M | Cambridge |
| Hemab | 2025 | Series C | $157.0M | Copenhagen |
| Tango Therapeutics | 2025 | Post Ipo Equity | $197.0M | Cambridge |
| Electra Therapeutics | 2025 | Series C | $183.0M | San Francisco |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 201 | Artios Pharma | Series D | $115.0M | Cambridge, United Kingdom |
| 202 | Invivyd | Post Ipo Equity | $125.0M | Waltham, United States |
| 203 | Imbria Pharmaceuticals | Series B | Undisclosed | Boston, United States |
| 204 | Bambusa Therapeutics | Series A | Undisclosed | Boston, United States |
| 205 | Biohaven Pharmaceutical | Post Ipo Equity | $200.0M | New Haven, United States |
| 206 | Azalea Therapeutics | Series A | $65.0M | Berkeley, United States |
| 207 | Seres Therapeutics | Grant | $3.6M | Cambridge, United States |
| 208 | Hemab | Series C | $157.0M | Copenhagen, Denmark |
| 209 | Tango Therapeutics | Post Ipo Equity | $197.0M | Cambridge, United States |
| 210 | Electra Therapeutics | Series C | $183.0M | San Francisco, United States |
Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field.
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
Imbria Pharmaceuticals is a clinical stage biotechnology company developing novel therapies for cardiometabolic diseases.
Bambusa Therapeutics operates as biotechnology company.
Biohaven is a biopharmaceutical company that develops drug candidates targeting neurological diseases.
Azalea Therapeutics is a biotechnology company with a primary focus on developing cancer immunotherapies.
Seres Therapeutics is a microbiome therapeutics company that develops treatments for serious diseases.
Hemab is a clinical-stage biotech company that develops prophylactic biologic therapies for underserved bleeding and thrombotic.
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Electra Therapeutics is a clinical-stage biotechnology company developing antibody therapies for immunological diseases and cancer.
VitriVax is a formulation technology company that engineers solutions to maximize the accessibility and utility of human vaccines.
Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC).
LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.
Indapta Therapeutics is a privately held biotechnology company.
TORL BioTherapeutics is a clinical-stage biopharmaceutical business.
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.
Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases.
Ansa Biotechnologies develops a novel DNA synthesis technology based on enzymes.
IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.
ARS Pharmaceuticals is a stealth pharmaceutical company that specializes in developing anti allergy drugs.
KalVista Pharmaceuticals is an ophthalmology company focused on developing drugs for the treatment of diabetic macular edema (DME).
PepGen is empowering nucleic acid therapeutics to go the distance.
Metalex Commodities is a commodity trading company that specializes in the export of metal ores and concentrates.
Synapse Energy Economics is a consulting firm providing economic and policy analysis for the electric power sector.
RA Capital Management has invested in 369 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 18 different industry categories.
Among tracked funding rounds, Avidity Biosciences received $690.0M in a Post Ipo Equity round. RA Capital Management's total known invested capital is $19.0B.
RA Capital Management's average investment size is $91.5M across its portfolio of 369 companies.
Recent RA Capital Management portfolio additions include Artios Pharma, Invivyd, Imbria Pharmaceuticals, Bambusa Therapeutics, Biohaven Pharmaceutical. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors